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A commentary on
Comparison of historical medical spending patterns among the BRICS and G7
by Jakovljevic, M. M. (2015). J. Med. Econ. 19, 70–76. doi: 10.3111/13696998.2015.1093493
Jakovljevic’s comparison of historical medical spending patterns between BRICS and G7 groups
of countries provides a highly valid contribution both from a group, as well as from an individual
nation perspective (Jakovljevic, 2015). The author considers two very diverse groups of countries in
terms of their wealth, population demographic profiles, as well as population health, health system
needs and medical spending patterns.
The first perspective is of an ethical nature and argued through the lens of the principles of
distributive justice intended for prioritizing populations on the basis of context, and in relation
to allocation of scarce healthcare resources. Two principles, often used interchangeably, are the
egalitarian and the equity principles. The former dictates serving those in need equally, whereas
the latter consents for contextual differences so that resources are allocated fairly and justly
(Persad et al., 2009; Hankins et al., 2015). In particular, equity justifies access to healthcare in that
utilization should echo the populations’ real needs and aims to eliminate socio-economic and other
obstacles. The comparison of the two groups provides a picture of global wealth inequality that is
likewise reflected in medical spending. It is therefore worth looking at additional demographic and
economic indicators as shown in Table 1 to gain a more holistic understanding of the inequalities.
The information in Table 1 clearly shows that the egalitarian principle is not supported in view
of the gross global wealth inequality in relation to the populations served; a situation that spills
over to healthcare. More challenging is upholding the equity principle in that one assumes that
the BRICS populations’ real needs far outweigh those of G7 countries, yet their share of Total
Health Expenditure (THE) as % of GDP is far less. Furthermore, the BRICS upward trend is
mainly dominated by China’s foremost contribution to medical spending trends worldwide. The
increasing ratio of THE as a % of GDP is an indication that the BRICS countries’ health expenditure
is growing at a fast rate. Furthermore, one might question the meaning of real need. Population
aging and chronic non-communicable diseases, referred to as “prosperity” diseases, appear to be
key expensive drivers for G7 countries. However, Jakovljevic also records a historical delay of these
drivers on THE in BRICS countries, which may justify the higher spending in G7 countries.
From a public health perspective, it is also wise to apply the widely used utilitarian principle of
distributive justice when allocating scarce medical resources, namely to achieve maximum benefit
to the maximum percentage of the world population. Conducting cost-effectiveness analysis is
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TABLE 1 | Demographic and economic indicators in BRICS and G7 groups of countries.
Demographic and
economic indicators
Groups of Countries
BRICS G7
Description of economy Five major emerging yet large and fast-growing national
economies (Sui and Sun, 2016)
Seven major advanced economies as acknowledged by
IMF (World Economic Outlook, 2016)
Population size 3 billion people or 42% of the world population (World
Economic Outlook, 2016)
750.47 million people or 10% of the world population
(Group of 7 countries (G7): Statistical Profile, 2016)
Combined nominal GDP Approximately 20% of the gross world GDP (World
Economic Outlook, 2016)
Approximately 39% of the gross world GDP (Group of 7
countries (G7): Statistical Profile, 2016)
Average total per capita health
spending
$1004 Purchase Power Parity (PPP) in 2013 (Jakovljevic,
2015)
$4747 PPP in 2013 (Jakovljevic, 2015)
important to choose the most effective health policy, albeit
potentially conflicting with ethical principles that do not rely
on the monetary value. This principle is however difficult
to assess in the report without delving deeper into the
countries’ disease burden and characteristics. Moreover, the
report challenges the readership to question the attainability
of WHO’s “Health for all-all for health!” (Hong, 2014) by
emphasizing the importance of long-term macro-economic
analysis and its influence on medical spending. Indeed, the
appreciation of the economic viewpoint enables international
health organizations and health policy makers to jointly reach
more meaningful explanations of the differences worldwide
when formulating policies on the provision and utilization
of healthcare resources and on overcoming health inequalities
worldwide.
The second perspective focuses on the downward trend in
all G7 countries’ share of THE to global THE in 1995-2013, in
contrast to the upward trend of the BRICS (with the exception
of South Africa). This raises hope that the gap in THE between
the two groups is diminishing. However, the stark differences
in % points for individual countries’ THE to global THE spells
out the reality that the gap is expected to remain wide for the
foreseeable future. Nevertheless, this report provides a rather
enlightening picture that “successful health reforms in leading
markets such as BRICS reveal a reshaping of their medical
care-related expenditures” (p. 70). Despite the “bold increase in
national health spending across the globe” (p. 70), the report
highlights medical innovation, rising public expectations and
extended longevity to explain the accelerated growth in health
care spending over time. Additionally, the author discusses
the two groups’ population demographic differences (aging
vs. younger nations) within the context of access to medical
care and population needs for healthcare. However, as the
author’s discussion indicates, these statistics alone do not reveal
sufficient information about whether spending is allocated
appropriately and efficiently. Therefore, further studies are
needed to determine and quantify the effect of these behavioral
drivers in particular to help curb wastage and misuse/abuse of
scarce resources. Additionally, barriers to global dissemination,
adoption and implementation of medical innovation, from G7
(often considered as world leaders in this sector) (Kesselheim
et al., 2013; Ma et al., 2014) to BRICS countries must be
researched. Furthermore, even after accounting for demographic
differences, public expectations in different nations/regions, e.g.,
North America rather than in groups of countries may help to
explain higher levels of medical spending. This calls for a better
understanding and quantifying of the value of needs vs. demands
and their drivers.
Finally, the report uses single source data to facilitate
comparisons. Additionally, the author considers 19 years of
observations as insufficient to uncover long-term THE trends. A
number of factors, which are usually expected to affect THE of a
country tend to vary over a long period rather than a short period
of time (e.g., changing population structures). The effect of such
factors might not be fully captured if the data set being used is
of a relatively short time frame. However, the counter-argument
is that longer periods may distort findings because of larger
variations over time particularly in medical and information
technology innovations that distinguished this period from the
previous decades.
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